Evotec has sold its chemical API manufacturing site in Halle/Westphalia to Monacum Partners.
The company sold the API manufacturing facility to the German Private Equity firm as part of its priority reset.
Through this initiative, Evotec aims to foster profitable growth within a more focused operational footprint — including drug discovery, development and manufacturing for biologics and other advanced therapies.
Evotec DS, situated in Halle/Westphalia, is a specialised CDMO with a strong foundation in chemical APIs and intermediates, as well as building blocks.
The company's offshoot is capable of providing an end-to-end service portfolio, which incorporates all stages of drug production from development to commercial-scale manufacturing.
By this acquisition by Monacum Partners, Evotec DS will have financial assistance in achieving its growth ambitions, while also benefitting from novel ownership.
Under the agreement, the workforce at Evotec DS — as well as business operations — will be incorporated into Monacum.
The company will also now operate under the name DAPIN GmbH.
[Image credit: Evotec DS]